產(chǎn)品英文名稱：X-VIVO™ 20 Chemically Defined, Serum-free Hematopoietic Cell Medium
產(chǎn)品中文名稱：X-VIVO™ 20 化學(xué)成分確定的無血清造血干細胞培養(yǎng)基

X-VIVO™ Chemically Defined, Serum-free Hematopoietic Cell Medium 研究背景
 Lonza’s R&D efforts and collaboration with many clinical trials have provided Lonza with the tools and expertise to support the developments in adoptive immunotherapy, cancer therapy, genetic therapy and other cellular therapies. Lonza’s philosophy for the development of serum-free formulations for use in cellular therapy is to provide a nutritionally complete and balanced environment for the cells. We have not included any exogenous growth factors, artificial stimulators of cellular proliferation or undefined supplements.
The products are devoid of any protein-kinase C stimulators and are suitable for the investigation of second messenger systems in the activation of human and murine lymphocytes. The formulations are complete and contain pharmaceutical grade human albumin, recombinant human insulin and pasteurized human transferrin. All X-VIVO™ Medium products are manufactured under current GMPs and are listed with the FDA in a product Master File. Permission to cross-reference the Master File may be obtained by contacting the Product Manager.

X-VIVO™ 15 Chemically Defined, Serum-free Hematopoietic Cell Medium 簡介
X-VIVO™ 20 Medium was developed and optimized to support the generation of LAK cells from monocyte-depleted PBL at high density. Initial cell densities between 2.0- 3.0 x 107 cells/ml were successfully used to generate LAK cells. X-VIVO™ Medium 20 may also be used as a growth medium for PBL and TIL.

 X-VIVO™ 20化學(xué)成分確定的無血清造血細胞培養(yǎng)基特點
» 不含血清
» 化學(xué)成份明確
» 成份包含L-谷氨酰胺，慶大霉素和酚紅
» 最適于無血清環(huán)境中腫瘤浸潤淋巴細胞(TIL)增殖

X-VIVO™ 20 Chemically Defined, Serum-free Hematopoietic Cell Medium 使用注意事項
1.X-VIVO™ 20 was developed and optimized to support the generation of LAK cells from monocyte-depleted PBL at high density. X-VIVO™ 20 contains L-glutamine, gentamicin, and phenol red.
2.Please see Supplemental Information for additional hematopoietic cell applications.